Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Triple Negative Breast Neoplasms: early-phase trial registry
7 of 11 indexed Triple Negative Breast Neoplasms trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,577 of 28,707 conditions by registered trial count.
11 US clinical trials · 7 currently recruiting · #1,577 of 28,707 conditions by registered trial count
Triple Negative Breast Neoplasms: 11 US clinical trials tracked, 7 recruiting.
Triple Negative Breast Neoplasms is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is Seagen, a wholly owned subsidiary of Pfizer, running 2 of these trials.
Enrollment posture brief
Registry condition triple-negative-breast-neoplasms
OPEN 7 | RECR 64% | LATE 4 | EARLY 7 | RANK #1577 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Advanced Melanoma (64% recruiting · 22 trials)
Triple Negative Breast Neoplasms lists 7 open slots (64% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Triple Negative Breast Neoplasms on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Triple Negative Breast Neoplasms is recruiting above its size-band peers.
7 of 11 indexed trials (63.6%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Triple Negative Breast Neoplasms research.
Seagen, a wholly owned subsidiary of Pfizer accounts for 2 of 11 trials (18.2%). 8 distinct sponsors appear on at least one study for this condition label.
-
Typical Triple Negative Breast Neoplasms enrolment sits around 329 participants.
Median target enrolment is 329 among the 11 trials that report a genuine target (sentinel values excluded). 1 of those (9.1%) plan for fewer than 100 participants.
-
Triple Negative Breast Neoplasms research is mostly interventional.
11 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
11 total, page 1 of 1
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Merck Sharp & Dohme
NCT06966700
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Merck Sharp & Dohme
NCT06841354
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT05208762
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
Eli Lilly and Company
NCT06400472
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
Baylor Breast Care Center
NCT05020860
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT06157892
A Study of Pembrolizumab and Cryoablation in People With Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT06246968
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
AstraZeneca
NCT03997123
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
BicycleTx Limited
NCT04561362
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
AstraZeneca
NCT03742102
Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss
Novartis Pharmaceuticals
NCT04251533
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 2 |
| Phase 3 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Triple Negative Breast Neoplasms records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Triple Negative Breast Neoplasms trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Triple Negative Breast Neoplasms page
11 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Triple Negative Breast Neoplasms trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Seagen, a wholly owned subsidiary of Pfizer sponsors the most Triple Negative Breast Neoplasms trials on record, review their full trial history before evaluating a specific study. See Seagen, a wholly owned subsidiary of Pfizer's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Triple Negative Breast Neoplasms condition card totals 11 registered trials; most-linked intervention Paclitaxel; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.